Renal drugdrug interactions: What we have learned and where we are going

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 4, 2012, Pages 433-448

  Lepist, Eve Irene ^a   Ray, Adrian S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Cimetidine; Digoxin; MATE1; Metformin; OAT1; Pgp; Probenecid; Pyrimethamine; Renal drug interactions

Indexed keywords

ABC TRANSPORTER; ACICLOVIR; ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; CEFALEXIN; CEFMETAZOLE; CIDOFOVIR; CIMETIDINE; CYTOCHROME P450; DOFETILIDE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; FAMOTIDINE; FEXOFENADINE; FUROSEMIDE; METFORMIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; OSELTAMIVIR; PENICILLIN G; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; PROBENECID; TENOFOVIR; UNINDEXED DRUG; XENOBIOTIC AGENT; CARRIER PROTEIN; DRUG; MATE1 PROTEIN, HUMAN; ORGANIC CATION TRANSPORTER;

BLOOD BRAIN BARRIER; CELL ASSAY; CHO CELL; DISEASE MODEL; DRUG ELIMINATION; DRUG MECHANISM; GLOMERULUS FILTRATION; HUMAN; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; METHODOLOGY; NONHUMAN; REVIEW; SOLUTE; ANIMAL; DRUG INTERACTION; GLOMERULUS; KIDNEY; KIDNEY TUBULE; METABOLISM;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CARRIER PROTEINS; DRUG INTERACTIONS; HUMANS; KIDNEY; KIDNEY GLOMERULUS; KIDNEY TUBULES; ORGANIC CATION TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; XENOBIOTICS;

EID: 84858820185     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.667401     Document Type: Review

References (150)

1. Lee CA, Cook JA, Reyner EL, Smith DA. P-glycoprotein related drug interactions: Clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 2010;6(5):603-19
2. European Medicines Agency. Guidelines on the investigation of drug interactions. 2010. Available from: Http://www.ema. europa.eu/ema/doc-index.jsp? curl=pages/includes/document/document-detail.jsp? webContentId= WC500090112&murl=menus/document-library/document-library. jsp&mid=0b01ac058009a3dc . The EMA guidelines recommend testing whether experimental drugs are substrates or inhibitors of Pgp, BCRP, bile salt export pump (BSEP), organic anion-transporting polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3), OCT1, OCT2, OAT1 and OAT3.
3. Food and Drug Administration. Guidance for Industry: Drug interaction studies study design, data analysis, and implications for dosing and labeling 2006. Available from: Http://www.fda. gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/UCM072101.pdf The FDA draft guidance introduced transporters as a potential source of clinically relevant drug-drug interactions, recommending that characterization of a drug candidate interaction with Pgp may be appropriate during drug development.
4. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9(3):215-36 . Paper providing the ITC recommendations for transporter screening including decision trees to determine whether a drug candidate may be a substrate or inhibitor of transporters implicated in DDIs and probe substrates and inhibitors to facilitate clinical studies. Transporters recommended for screening by the ITC are Pgp, BCRP, OATP1B1, OATP1B3, OCT2, OAT1 and OAT3.
5. Lin JH. Transporter-mediated drug interactions: Clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 2007;3(1):81-92
6. Masereeuw R, Russel FG. Therapeutic implications of renal anionic drug transporters. Pharmacol Ther 2010;126(2):200-16
7. Zhang L, Huang SM, Lesko LJ. Transporter-mediated drug-drug interactions. Clin Pharmacol Ther 2011;89(4):481-4
8. Muller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics 2011;12(7):1017-37
9. Dresser MJ, Leabman MK, Giacomini KM. Transporters involved in the elimination of drugs in the kidney: Organic anion transporters and organic cation transporters. J Pharm Sci 2001;90(4):397-421
10. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004;44:137-66
11. Launay-Vacher V, Izzedine H, Karie S, et al. Renal tubular drug transporters. Nephron Physiol 2006;103(3):97-106
12. Burckhardt G, Burckhardt BC. In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy. Handb Exp Pharmacol 2011(201):29-104
13. Sekine T, Watanabe N, Hosoyamada M, et al. Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem 1997;272(30):18526-9
14. Sweet DH, Wolff NA, Pritchard JB. Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem 1997;272(48):30088-95
15. Cihlar T, Lin DC, Pritchard JB, et al. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol 1999;56(3):570-80
16. Reid G, Wolff NA, Dautzenberg FM, Burckhardt G. Cloning of a human renal p-aminohippurate transporter, hROAT1. Kidney Blood Press Res 1998;21(2-4):233-7 First paper to characterize the human OAT1 transporter.
17. Kusuhara H, Sekine T, Utsunomiya-Tate N, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 1999;274(19):13675-80
18. Race JE, Grassl SM, Williams WJ, Holtzman EJ. Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). Biochem Biophys Res Commun 1999;255(2):508-14 First paper to characterize the human OAT3 transporter.
19. Sweet DH, Chan LM, Walden R, et al. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol Renal Physiol 2003;284(4):763-9
20. Ekaratanawong S, Anzai N, Jutabha P, et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharm Sci 2004;94(3):297-304
21. Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007;18(2):430-9
22. Khamdang S, Takeda M, Babu E, et al. Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol 2003;465(1-2):1-7
23. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417(6887):447-52
24. Bahn A, Hagos Y, Reuter S, et al. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 2008;283(24):16332-41
25. Mikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 2004;101(10):3569-74
26. Uchino H, Tamai I, Yamashita K, et al. p-aminohippuric acid transport at renal apical membrane mediated by human inorganic phosphate transporter NPT1. Biochem Biophys Res Commun 2000;270(1):254-9
27. Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol 2007;19(2):151-7
28. Iharada M, Miyaji T, Fujimoto T, et al. Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)- dependent urate exporter. J Biol Chem 2010;285(34):26107-13
29. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24(7):1227-51
30. Gorboulev V, Ulzheimer JC, Akhoundova A, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 1997;16(7):871-81 First paper to characterize the human OCT2 transporter.
31. Okuda M, Saito H, Urakami Y, et al. cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun 1996;224(2):500-7
32. Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol 2011(201):105-67 Recent comprehensive overview of organic cation transporters.
33. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, et al. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: Functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010;298(4):997-1005
34. Otsuka M, Matsumoto T, Morimoto R, et al. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005;102(50):17923-8 . First paper to characterize the human MATE1 transporter.
35. Masuda S, Terada T, Yonezawa A, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006;17(8):2127-35
36. Tanihara Y, Masuda S, Sato T, et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol 2007;74(2):359-71
37. Yonezawa A, Inui K. Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. Br J Pharmacol 2011;164(7):1817-25 Recent comprehensive review of MATE transporters.
38. Damme K, Nies AT, Schaeffeler E, Schwab M. Mammalian MATE (SLC47A) transport proteins: Impact on efflux of endogenous substrates and xenobiotics. Drug Metab Rev 2011;43(4):499-523
39. Tamai I, Ohashi R, Nezu J, et al. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 1998;273(32):20378-82
40. Tamai I, Yabuuchi H, Nezu J, et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 1997;419(1):107-11
41. Wu X, Huang W, Prasad PD, et al. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 1999;290(3):1482-92
42. Yabuuchi H, Tamai I, Nezu J, et al. Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J Pharmacol Exp Ther 1999;289(2):768-73
43. Ohashi R, Tamai I, Yabuuchi H, et al. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): Its pharmacological and toxicological relevance. J Pharmacol Exp Ther 1999;291(2):778-84
44. Barnes K, Dobrzynski H, Foppolo S, et al. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 2006;99(5):510-19
45. Damaraju VL, Elwi AN, Hunter C, et al. Localization of broadly selective equilibrative and concentrative nucleoside transporters, hENT1 and hCNT3, in human kidney. Am J Physiol Renal Physiol 2007;293(1):200-11
46. Govindarajan R, Bakken AH, Hudkins KL, et al. In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Physiol Regul Integr Comp Physiol 2007;293(5):1809-22
47. Elwi AN, Damaraju VL, Kuzma ML, et al. Transepithelial fluxes of adenosine and 2'-deoxyadenosine across human renal proximal tubule cells: Roles of nucleoside transporters hENT1, hENT2, and hCNT3. Am J Physiol Renal Physiol 2009;296(6):1439-51
48. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, et al. Cell entry and export of nucleoside analogues. Virus Res 2005;107(2):151-64
49. Elwi AN, Damaraju VL, Baldwin SA, et al. Renal nucleoside transporters: Physiological and clinical implications. Biochem Cell Biol 2006;84(6):844-58
50. Li M, Anderson GD, Phillips BR, et al. Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos 2006;34(4):547-55
51. Liu R, Tang AM, Tan YL, et al. Effects of sodium bicarbonate and ammonium chloride pre-treatments on PEPT2 (SLC15A2) mediated renal clearance of cephalexin in healthy subjects. Drug Metab Pharmacokinet 2011;26(1):87-93
52. Liu W, Liang R, Ramamoorthy S, et al. Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidney. Biochim Biophys Acta 1995;1235(2):461-6
53. Ganapathy ME, Brandsch M, Prasad PD, et al. Differential recognition of beta -lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J Biol Chem 1995;270(43):25672-7
54. Ganapathy ME, Huang W, Wang H, et al. Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem Biophys Res Commun 1998;246(2):470-5
55. Temple CS, Boyd CA. Proton-coupled oligopeptide transport by rat renal cortical brush border membrane vesicles: A functional analysis using ACE inhibitors to determine the isoform of the transporter. Biochim Biophys Acta 1998;1373(1):277-81
56. Brandsch M, Knutter I, Bosse-Doenecke E. Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 2008;60(5):543-85
57. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84(21):7735-8
58. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42(3):155-99
59. Cascorbi I. P-glycoprotein: Tissue distribution, substrates, and functional consequences of genetic variations. Handb Exp Pharmacol 2011(201):261-83 Comprehensive review of P-glycoprotein.
60. Nies AT, Rius M, Keppler D. Multidrug resistance proteins of the ABCC superfamily. In: You G, Morris ME, editors. Drug Transporters: Molecular Characterization and Role in Drug Disposition. Wiley; Hoboken NJ: 2007. p. 263-318
61. Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol 1996;148(4):1237-47
62. Schaub TP, Kartenbeck J, Konig J, et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 1999;10(6):1159-69
63. Belinsky MG, Chen ZS, Shchaveleva I, et al. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 2002;62(21):6172-7
64. Borst P, van de Wetering K, Schlingemann R. Does the absence of ABCC6 (multidrug resistance protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery? Cell Cycle 2008;7(11):1575-9
65. Huls M, Brown CD, Windass AS, et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 2008;73(2):220-5 Paper demonstrating localization of BCRP on the apical membrane in the human proximal tubule.
66. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem 2003;278(25):22644-9
67. Woodward OM, Kottgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 2009;106(25):10338-42
68. Meyer zu Schwabedissen HE, Kroemer HK. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exper Pharmacol 2011(201):325-71
69. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001;20(4-7):641-8
70. Cihlar T, Ray AS, Laflamme G, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007;12(2):267-72
71. Imaoka T, Kusuhara H, Adachi M, et al. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol 2007;71(2):619-27
72. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother 2006;50(10):3297-304
73. Chu XY, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321(2):673-83
74. Lai Y, Sampson KE, Balogh LM, et al. Preclinical and clinical evidence for the collaborative transport and renal secretion of an oxazolidinone antibiotic by organic anion transporter 3 (OAT3/SLC22A8) and multidrug and toxin extrusion protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther 2010;334(3):936-44 . Paper describing active tubular secretion by OAT3 and MATE1, transporters commonly thought of as members of distinct anion and cation active tubular secretion pathways.
75. Lai Y, Sampson KE, Stevens JC. Evaluation of drug transporter interactions in drug discovery and development. Comb Chem High Throughput Screen 2010;13(2):112-34
76. Lu C, Liao M, Cohen L, Xia CQ. Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions. Curr Drug Discov Technol 2010;7(3):199-222
77. Horio M, Gottesman MM, Pastan I. ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci USA 1988;85(10):3580-4
78. Keppler D, Jedlitschky G, Leier I. Transport function and substrate specificity of multidrug resistance protein. Methods Enzymol 1998;292:607-16
79. Sarkadi B, Price EM, Boucher RC, et al. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992;267(7):4854-8
80. Urbatsch IL, Sankaran B, Weber J, Senior AE. P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J Biol Chem 1995;270(33):19383-90
81. Pritchard JB, Miller DS. Mechanisms mediating renal secretion of organic anions and cations. Physiol Rev 1993;73(4):765-96
82. Cihlar T, Laflamme G, Fisher R, et al. Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: Characterization of renal transport and accumulation. Antimicrob Agents Chemother 2009;53(1):150-6
83. Nozaki Y, Kusuhara H, Kondo T, et al. Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices. J Pharmacol Exp Ther 2007;321(1):362-9
84. Konig J, Zolk O, Singer K, et al. Double-transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: Determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol 2011;163(3):546-55
85. Sato T, Masuda S, Yonezawa A, et al. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem Pharmacol 2008;76(7):894-903
86. Kopplow K, Letschert K, Konig J, et al. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol 2005;68(4):1031-8
87. Matsushima S, Maeda K, Kondo C, et al. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 2005;314(3):1059-67
88. Tsuda M, Terada T, Ueba M, et al. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 2009;329(1):185-91 . Study illustrating inhibition of MATE1 and not OCT2 as the most likely mechanism for the renal DDI observed between cimetidine and metformin.
89. Brown CD, Sayer R, Windass AS, et al. Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol 2008;233(3):428-38
90. Wilmer MJ, Saleem MA, Masereeuw R, et al. Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res 2010;339(2):449-57
91. Tahara H, Kusuhara H, Endou H, et al. A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther 2005;315(1):337-45
92. Suzuyama N, Katoh M, Takeuchi T, et al. Species differences of inhibitory effects on P-glycoprotein-mediated drug transport. J Pharm Sci 2007;96(6):1609-18
93. Enomoto A, Takeda M, Shimoda M, et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther 2002;301(3):797-802
94. Kojima R, Sekine T, Kawachi M, et al. Immunolocalization of multispecific organic anion transporters, OAT1, OAT2, and OAT3, in rat kidney. J Am Soc Nephrol 2002;13(4):848-57
95. Tahara H, Kusuhara H, Maeda K, et al. Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid. Drug Metab Dispos 2006;34(5):743-7
96. Tahara H, Kusuhara H, Chida M, et al. Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol Exp Ther 2006;316(3):1187-94
97. Robbins N, Koch SE, Tranter M, Rubinstein J. The History and Future of Probenecid. Cardiovasc Toxicol 2012;12(1):1-9
98. Hill G, Cihlar T, Oo C, et al. The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos 2002;30(1):13-19
99. Burnell JM, Kirby WM. Effectiveness of a new compound, benemid, in elevating serum penicillin concentrations. J Clin Invest 1951;30(7):697-700
100. Takeda M, Narikawa S, Hosoyamada M, et al. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol 2001;419(2-3):113-20
101. Selen A, Amidon GL, Welling PG. Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci 1982;71(11):1238-42
102. Ueo H, Motohashi H, Katsura T, Inui K. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol 2005;70(7):1104-13
103. Cundy KC, Petty BG, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1995;39(6):1247-52
104. Cundy KC, Li ZH, Lee WA. Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Drug Metab Dispos 1996;24(3):315-21
105. Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharm 1983;25(3):339-45
106. Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987;23(5):545-51
107. Ito S, Kusuhara H, Yokochi M, et al. Competitive inhibition of the luminal efflux by MATEs, but not basolateral uptake by OCT2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther 2011; Epub ahead of print
108. Ito S, Kusuhara H, Kuroiwa Y, et al. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 2010;333(1):341-50 . Identifies pyrimethamine as a potent and relatively selective inhibitor of MATE1.
109. Kusuhara H, Ito S, Kumagai Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011;89(6):837-44 Clinical study showing that, similar to cimetidine, the MATE1 inhibitor pyrimethamine has a renal DDI with metformin.
110. van Acker BA, Koomen GC, Koopman MG, et al. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 1992;340(8831):1326-9
111. Opravil M, Keusch G, Luthy R. Pyrimethamine inhibits renal secretion of creatinine. Antimicrob Agents Chemother 1993;37(5):1056-60
112. Polli JW, Jarrett JL, Studenberg SD, et al. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 1999;16(8):1206-12 . Report illustrating the difficulty in obtaining sufficient systemic drug levels to inhibit transporters by showing that ritonavir is unable to inhibit Pgp at the blood-brain barrier in mice.
113. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 2004;76(1):73-84
114. Hager WD, Fenster P, Mayersohn M, et al. Digoxin-quinidine interaction Pharmacokinetic evaluation. N Engl J Med 1979;300(22):1238-41
115. Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit 1997;19(6):609-13
116. Pedersen KE, Dorph-Pedersen A, Hvidt S, et al. The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol 1982;22(2):123-7
117. Koren G, Woodland C, Ito S. Toxic digoxin-drug interactions: The major role of renal P-glycoprotein. Vet Hum Toxicol 1998;40(1):45-6
118. Penzak SR, Shen JM, Alfaro RM, et al. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit 2004;26(3):322-30
119. Shapiro B, Kollmann GJ, Heine WI. Pitfalls in the application of digoxin determinations. Semin Nucl Med 1975;5(3):205-20
120. Drescher S, Glaeser H, Murdter T, et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003;73(3):223-31
121. Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: Impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995;22(11):2072-7
122. Apiwattanakul N, Sekine T, Chairoungdua A, et al. Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes. Mol Pharmacol 1999;55(5):847-54
123. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther 2007;320(1):229-35
124. Iqbal MP, Baig JA, Ali AA, et al. The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Biopharm Drug Dispos 1998;19(3):163-7
125. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: The role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003;37(12):174-6
126. Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther 2008;83(2):265-72
127. Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007;51(10):3498-34504
128. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis 2011;204(1):145-53
129. Laskin OL, de Miranda P, King DH, et al. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother 1982;21(5):804-7
130. Wada S, Tsuda M, Sekine T, et al. Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther 2000;294(3):844-9
131. Ko H, Cathcart KS, Griffith DL, et al. Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination. Antimicrob Agents Chemother 1989;33(3):356-61
132. Inotsume N, Nishimura M, Nakano M, et al. The inhibitory effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J Clin Pharmacol 1990;30(1):50-6
133. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 2005;77(1):17-23
134. Honari J, Blair AD, Cutler RE. Effects of probenecid on furosemide kinetics and natriuresis in man. Clin Pharmacol Ther 1977;22(4):395-401
135. Vallon V, Rieg T, Ahn SY, et al. Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol 2008;294(4):867-73
136. Jariyawat S, Sekine T, Takeda M, et al. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther 1999;290(2):672-7
137. Abel S, Nichols DJ, Brearley CJ, Eve MD. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 2000;49(1):64-71
138. Jayasagar G, Krishna Kumar M, Chandrasekhar K, et al. Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers. Drug Metabol Drug Interact 2002;19(1):41-8
139. Shiga T, Hashiguchi M, Urae A, et al. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther 2000;67(3):222-8
140. Tsuruoka S, Ioka T, Wakaumi M, et al. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: First case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. Clin Pharmacol Ther 2006;79(4):389-96
141. Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther 1992;51(4):379-87
142. Kaewmokul S, Chatsudthipong V, Evans KK, et al. Functional mapping of rbOCT1 and rbOCT2 activity in the S2 segment of rabbit proximal tubule. Am J Physiol Renal Physiol 2003;285(6):1149-59
143. Bauer LA, Black DJ, Lill JS, et al. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances. Antimicrob Agents Chemother 2005;49(4):1649-51
144. Martin DE, Shen J, Griener J, et al. Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide. J Clin Pharmacol 1996;36(1):85-91
145. Muller F, Konig J, Glaeser H, et al. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother 2011;55(7):3091-8
146. Kosoglou T, Rocci ML Jr, Vlasses PH. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Clin Pharmacol Ther 1988;44(4):467-77
147. de Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992;189(1):551-7
148. Gutmann H, Fricker G, Drewe J, et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999;56(2):383-9
149. De Lannoy IA, Koren G, Klein J, et al. Cyclosporin and quinidine inhibition of renal digoxin excretion: Evidence for luminal secretion of digoxin. Am J Physiol 1992;263(4 Pt 2):613-22
150. Karyekar CS, Eddington ND, Briglia A, et al. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol 2004;44(8):919-27